fulranumab   

GtoPdb Ligand ID: 8964

Synonyms: AMG-403 | JNJ-42160443
Compound class: Antibody
Comment: Fulranumab was an investigational, fully human IgG2κ monoclonal antibody targeting nerve growth factor (NGF) [1,6].
Peptide sequence information for this antibody is available from its IMGT/mAb-DB record.
BLAST peptide sequence analysis reveals identical matches to peptide sequences submitted with patent US7601818 [9], which belong to antibody clone 4D4 therein.
No information available.
Summary of Clinical Use
Fulranumab progressed to Phase 3 clinical trial as a potential therapy for pain associated with osteoarthritis of the hip or knee, either as a monotherapy or as an adjunct to non-steroidal anti-inflammatory treatment. However, despite demonstraing safety and efficacy in earlier trials [7-8], all fulranumab clinical studies were prematurely discontinued by the sponsor (Janssen Research & Development) in early 2016, for business reasons [4]. Kelly et al. (2019) analysed the limited data available from the terminated Phase 3 studies, which confirmed the safety and efficacy of this anti-NGF antibody in osteoarthritis pain mitigation [5].
Mechanism Of Action and Pharmacodynamic Effects
An extensive body of evidence indicates a pivotal contribution of NGF to pain mechanisms in the adult mammalian nervous system, with elevated levels of NGF reported in several painful conditions in humans [2-3]. Fulranumab specifically neutralizes the biological actions of human NGF, producing sustained clinical pain relief [6].